# Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab

> **NCT01845844** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Southeast Retina Center, Georgia** · enrollment: 30 (estimated)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Ranibizumab 0.3mg/0.05cc

## Key facts

- **NCT ID:** NCT01845844
- **Lead sponsor:** Southeast Retina Center, Georgia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2014-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01845844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01845844, "Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01845844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*